Literature DB >> 25552703

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Pierre Peterlin1, Aline Renneville2, Raouf Ben Abdelali3, Olivier Nibourel2, Xavier Thomas4, Cécile Pautas5, Stéphane de Botton6, Emmanuel Raffoux7, Jean-Michel Cayuela8, Nicolas Boissel7, Christine Terré9, Karine Celli-Lebras10, Sylvie Castaigne11, Claude Preudhomme2, Claude Gardin12, Hervé Dombret13.   

Abstract

Entities:  

Keywords:  CN-AML heterogeneity; NPM1 mutation; cytogenetically normal

Mesh：

Substances：

Year:  2014        PMID： 25552703      PMCID： PMC4420231          DOI： 10.3324/haematol.2014.115576

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Authors:  Brunangelo Falini; Cristina Mecucci; Enrico Tiacci; Myriam Alcalay; Roberto Rosati; Laura Pasqualucci; Roberta La Starza; Daniela Diverio; Emanuela Colombo; Antonella Santucci; Barbara Bigerna; Roberta Pacini; Alessandra Pucciarini; Arcangelo Liso; Marco Vignetti; Paola Fazi; Natalia Meani; Valentina Pettirossi; Giuseppe Saglio; Franco Mandelli; Francesco Lo-Coco; Pier-Giuseppe Pelicci; Massimo F Martelli
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

2.  Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.

Authors:  Guido Marcucci; Klaus H Metzeler; Sebastian Schwind; Heiko Becker; Kati Maharry; Krzysztof Mrózek; Michael D Radmacher; Jessica Kohlschmidt; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

3.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Authors:  Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

4.  Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.

Authors:  Xavier Thomas; Mohamed Elhamri; Emmanuel Raffoux; Aline Renneville; Cécile Pautas; Stéphane de Botton; Thierry de Revel; Oumedaly Reman; Christine Terré; Claude Gardin; Youcef Chelghoum; Nicolas Boissel; Bruno Quesnel; Yosr Hicheri; Jean-Henri Bourhis; Pierre Fenaux; Claude Preudhomme; Mauricette Michallet; Sylvie Castaigne; Hervé Dombret
Journal:  Blood       Date:  2011-06-20       Impact factor: 22.113

5.  Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.

Authors:  M Ryan Corces-Zimmerman; Wan-Jen Hong; Irving L Weissman; Bruno C Medeiros; Ravindra Majeti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 6.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

7.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

8.  Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.

Authors:  Cecile Pautas; Fatiha Merabet; Xavier Thomas; Emmanuel Raffoux; Claude Gardin; Selim Corm; Jean-Henri Bourhis; Oumedaly Reman; Pascal Turlure; Nathalie Contentin; Thierry de Revel; Philippe Rousselot; Claude Preudhomme; Dominique Bordessoule; Pierre Fenaux; Christine Terré; Mauricette Michallet; Hervé Dombret; Sylvie Chevret; Sylvie Castaigne
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

9.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Kati Maharry; Yue-Zhong Wu; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Susan P Whitman; Heiko Becker; Sebastian Schwind; Klaus H Metzeler; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 50.717

10.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717
View more
  3 in total

1.  [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].

Authors:  T Zhao; H H Zhu; J Wang; J S Jia; S M Yang; H Jiang; J Lu; H Chen; L P Xu; X H Zhang; B Jiang; G R Ruan; D B Wang; X J Huang; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-01-14

2.  Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia.

Authors:  Nikhil Patkar; Rohan Kodgule; Chinmayee Kakirde; Goutham Raval; Prasanna Bhanshe; Swapnali Joshi; Shruti Chaudhary; Y Badrinath; Sitaram Ghoghale; Shraddha Kadechkar; Syed Hasan Khizer; Sadhana Kannan; Dhanalaxmi Shetty; Anant Gokarn; Sachin Punatkar; Hasmukh Jain; Bhausaheb Bagal; Hari Menon; Manju Sengar; Navin Khattry; Prashant Tembhare; Papagudi Subramanian; Sumeet Gujral
Journal:  Oncotarget       Date:  2018-11-27

Review 3.  IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.

Authors:  Johanna Mondesir; Christophe Willekens; Mehdi Touat; Stéphane de Botton
Journal:  J Blood Med       Date:  2016-09-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.